The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward-Reference-Cited by-同舟云学术

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward

Published:2019-04 Issue:4 Volume:95 Page:747-749
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Rossignol Patrick,Frimat Luc,Zannad Faiez

Funder

French National Research Agency

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. Roadmap for cardiovascular prevention trials in chronic kidney disease;Rossignol;Lancet,2016

2. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure;Ortiz;Lancet,2014

3. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints;Rossignol;Eur Heart J,2017

4. Blood pressure and mortality among hemodialysis patients;Agarwal;Hypertension,2010

5. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis;Pitt;J Am Coll Cardiol,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path;Reviews in Cardiovascular Medicine;2024-06-25

2. Overview of research progress on the association of dietary potassium intake with serum potassium and survival in hemodialysis patients, does dietary potassium restriction really benefit hemodialysis patients?;Frontiers in Endocrinology;2023-11-29

3. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA);Clinical Kidney Journal;2023-06-24

4. Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review;Journal of Cardiovascular Development and Disease;2023-05-28

5. Mineralocorticoid receptor antagonist use in renal dialysis: will evidence from prospective randomized trials confirm the results from ‘real‐world’ evidence?;European Journal of Heart Failure;2023-03